Product Details
| Product Name:
LY341495 |
CAS No.:
201943-63-7 |
| Purity:
99.37% |
Supply Ability:
10g |
| Release date:
2025/12/22 |
Product Introduction
Bioactivity
| Name | LY341495 |
| Description | LY341495 is a potent metabotropic glutamate receptor antagonist that exhibits high activity against a wide range of glutamate receptor subtypes and can be used for the study of neurological disorders. |
| In vivo | Acute administration of LY341495 (3.0 mg/kg) reduces levels of pAkt and pGSK-3, but repeated administration (3.0 mg/kg) is required to decrease β-catenin levels[2]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5 mg/mL (14.15 mM), Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
|
| Keywords | mGluR-8, human | mGluR-3, human | mGluR-2, human | mGluR1 | LY-341495 | LY341495 | LY 341495 |
| Inhibitors Related | IDRA-21 | Urethane | Decanoic Acid | L-Cysteic acid monohydrate | DCB | Evans blue | L-Glutamine | Direct Blue 1 | L-Glutamic acid monosodium salt | Piracetam | O-Phospho-L-serine | Memantine hydrochloride |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States